Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

12/03/2021 | 10:01am EST

TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam's RNAi Platform Collaboration Update – at 2:00 p.m. ET on Monday, December 6, 2021.

Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center, will participate on behalf of Regeneron.

The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations                                             
Mark Hudson                                                             
914.847.3482                                                    
mark.hudson@regeneron.com

Cision
View original content:https://www.prnewswire.com/news-releases/regeneron-to-participate-in-hc-wainwright--co-virtual-event-301437162.html

SOURCE Regeneron Pharmaceuticals, Inc.


ę PRNewswire 2021
All news about REGENERON PHARMACEUTICALS
07:54aRegeneron Says US FDA Accepts for Review its Supplemental BLA for Libtayo in Combinatio..
MT
07:37aRegeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
DJ
07:01aFDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
PR
04:00aSanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
MT
01:35aSanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
MT
01:00aSecond Positive Phase 3 Dupixent« (dupilumab) Trial Confirms Significant Improvements f..
PR
01/18Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $585 From $617, Mainta..
MT
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results a..
PR
01/12EUROPEAN MIDDAY BRIEFING - Stocks Higher as -3-
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations